Loading data for VRXA — first visit, this takes a few seconds.
Veraxa Biotech AG (VRXA)
NasdaqGM: VRXA
· Echtzeitkurs · USD
1.86
-0.01 (-0.53%)
Zum Schluss: Aug 17, 2026, 8:00 PM
1.84
-1.06%
Vorbörslich: 4:35 AM
Veraxa Biotech AG (VRXA) Stock Price, Analysis & Data
-0.53% (1D)
Keine Daten verfügbar
| Geld | 1.85 |
| Marktkapitalisierung | 263.02 Mio |
| Umsatz (TTM) | n/a |
| Nettogewinn (TTM) | n/a |
| Beta | n/a |
| EPS (ttm) | -0.57 |
| KGV (TTM) | n/a |
| Forward-KGV | n/a |
| KBV (TTM) | n/a |
| KUV (TTM) | n/a |
| Earnings Date | n/a |
| Brief | 1.9 |
| Volumen | 47,185 |
| Ø Vol. (20D) | 461,519 |
| Eröffnung | 1.87 |
| Vortagesschluss | 1.87 |
| Tagesspanne | 1.81 - 1.88 |
| 52-Wk Range | 1.70 - 27.36 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über VRXA
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partn...
Branche Biotechnology
Sektor Healthcare
IPO Datum Sep 30, 2024
Mitarbeiter n/a
Börse NasdaqGM
Tickersymbol VRXA
Website https://www.veraxa.com
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Veraxa Biotech 23.43K, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -66.61 Mio, ein Anstieg von 136.78 %.
Finanzberichte
